期刊文献+

综合护理在HIV并HBV患者行替诺福韦联合拉米夫定抗病毒治疗中的应用价值 被引量:1

Application Value of Comprehensive Nursing in Anti-viral Therapy of Tenofovir Combined with Lamivudine in Patients with HIV and HBV Infection
下载PDF
导出
摘要 目的:探讨综合护理在人类免疫缺陷病毒(HIV)合并乙型肝炎病毒(HBV)患者行替诺福韦联合拉米夫定抗病毒治疗中的应用价值。方法:从本院2017年8月至2019年5月收治的行替诺福韦联合拉米夫定抗病毒治疗的HIV并HBV患者中选取48例作为研究对象,采用数字盲选法,划分为Ⅰ组(n=24,常规护理)和Ⅱ组(n=24,综合护理),对比两组CD4+淋巴细胞水平、血清学转换、护理满意度。结果:实施综合护理后,Ⅱ组患者CD4+淋巴细胞水平明显比Ⅰ组高;经护理,Ⅱ组患者血清转换率明显比Ⅰ组高;Ⅱ组患者的焦虑自评量表(SAS)和抑郁自评量表(SDS)评分均比Ⅰ组低。两组比较差异显著(P<0.05)。结论:在行替诺福韦联合拉米夫定抗病毒治疗中采用综合护理模式,HIV并HBV患者CD4+淋巴细胞水平、血清转换率等明显提高,使患者的焦虑、抑郁等负性情绪得到了有效缓解。 Objective:To explore the application value of comprehensive nursing in anti-viral therapy of tenofovir combined with lamivudine in patients with HIV and HBV infection.Methods:In our hospital between August 2017 and May 2019 were rows of tenofovir combined lamivudine antiviral treatment in patients with HIV and HBV from 48 cases as the research object,adopting digital blind method,divided intoⅠgroup(n=24,routine nursing)andⅡgroup(n=24,comprehensive care),compared two groups of CD4+lymphocytes level,seroconversion,nursing satisfaction.Results:After comprehensive nursing,level of CD4+lymphocytes in patients withⅡgroup was obviously higher thanⅠgroup;Patients serum conversion rate after nursing,Ⅱgroup was obviously higher thanⅠgroup;Ⅱgroup of patients with SAS,SDS scores were lower thanⅠgroup.The difference between the two groups was significant(P<0.05).Conclusion:The comprehensive nursing mode adopted in the antiviral treatment of tenofovir combined with lamivudine significantly improved CD4+lymphocyte level and serum conversion rate in patients with HIV and HBV,effectively alleviated the negative emotions such as anxiety and depression.
作者 饶红梅 RAO Hong-mei(Fuzhou First People’s Hospital,Fuzhou Jiangxi 344000,China)
出处 《药品评价》 CAS 2020年第2期69-70,共2页 Drug Evaluation
关键词 综合护理 替诺福韦 拉米夫定 抗病毒 Comprehensive Nursing Tenofovir Lamivudine Antiviral
  • 相关文献

参考文献9

二级参考文献64

  • 1陈仁芳,郑毓芳,徐淑凡,杨琦恩,陆宇红,蒋亦明.基于替诺福韦和拉米夫定初始联合的高效抗反转录病毒治疗艾滋病合并乙型肝炎病毒感染72周的疗效[J].中华临床感染病杂志,2013,6(3):153-156. 被引量:10
  • 2Ly Q Hong-Brown,Abid A Kazi,Charles H Lang.Mechanisms mediating the effects of alcohol and HIV anti-retroviral agents on mTORC1,mTORC2 and protein synthesis in myocytes[J].World Journal of Biological Chemistry,2012,3(6):110-120. 被引量:2
  • 3王爱霞,王福生,王清玥,王健,冯铁建,卢洪洲,孙洪清,孙永涛,叶寒辉,李太生,李兴旺,刘正印,邢玉兰,何云,汪宁,吴昊,吴南屏,张福杰,周曾全,宫恩聪,赵红心,赵敏,唐小平,徐莲芝,徐小元,曹韵贞,康来仪,蒋岩,蔡卫平,樊庆泊,潘孝彰.艾滋病诊疗指南[J].中华传染病杂志,2006,24(2):133-144. 被引量:630
  • 4Leung N. Treatment of chronic hepatitis B: case selection and duration oftherapy[J]. J Gastroenterol Hepatol, 2002, 17(4): 409-414.
  • 5Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection[J]. Dig Dis Sci, 2014, 60(5): 1457-1464. DOl: 10. 1007/s 10620-0 14-3486-7.
  • 6Ke W, Liu L, Zhang C, et al. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis[J]. PLoS One, 2014, 9(6): e98865. DOl: 10.13711journal.pone.0098865.
  • 7Gao L, Trinh HN, Li J, et al. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther, 2014,39(6): 629-637. DOl: 1O.l11l1apt.12629.
  • 8Choi K, Lee HM, Jun BG, et al. Efficacy oftenofovir-based rescue therapy for patients with drug-resistant chronic hepatitis B[J]. Korean J Gastroenterol, 2015, 65(1): 35-42.
  • 9Lim YS, Yoo BC, Byun KS, et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial[J]. Gut, 2015. DOl: 1O.l136/guYnl-2014-308435.
  • 10van Bommel F, Wiinsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of larnivudine-resistant hepatis B virus infection[J]. Hepatology, 2004, 40(6): 1421-1425.

共引文献81

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部